Detailed Analysis of U.S. Patent 6,468,967: Scope, Claims, and Patent Landscape
What does U.S. Patent 6,468,967 cover?
U.S. Patent 6,468,967, granted on October 22, 2002, is titled "Methods for inhibiting apoptosis and treating diseases associated with apoptosis." The patent primarily claims methods involving compounds that inhibit programmed cell death, especially in the context of neurodegenerative diseases, ischemic conditions, and other conditions where apoptosis contributes to pathology.
Key Features:
- Focuses on cyclic peptides and peptide mimetics.
- Describes methods to administer compounds to inhibit apoptosis.
- Targets diseases like stroke, neurodegenerative disorders, and HIV-associated illnesses.
- Claims include specific peptide sequences and their pharmaceutical compositions.
What are the core claims?
The claims define the scope of protected inventions. They are categorized into method claims, composition claims, and specific peptide sequences.
Main claims include:
Claim 1: A method of inhibiting apoptosis comprising administering a therapeutically effective amount of a cyclic peptide or a peptidomimetic which inhibits caspase activity.
Claim 2: The cyclic peptide of Claim 1, wherein the peptide contains a sequence with a general formula involving intercyclic bonds.
Claim 3: A pharmaceutical composition comprising a cyclic peptide as described, combined with a pharmaceutically acceptable carrier.
Claim 4: A method involving administering a peptide that mimics the activity of the endogenous inhibitors of apoptosis proteins (IAPs).
Claims 5-12: Variations of peptide sequences, methods of synthesis, and specific disease conditions for treatment.
Notable claim limitations:
- Specific peptide sequences (e.g., cyclic peptides with particular amino acid arrangements).
- Methods of stimulating or inhibiting particular caspases.
- Inclusion of pharmaceutical formulations.
Patent landscape overview
Prior art and related patents:
- The patent builds on earlier caspase and apoptosis-related patents, notably those by Cambridge and UCLA researchers.
- Contains specific claims on cyclic peptides designed to modulate apoptosis, which distinguishes it from earlier linear peptide inhibitors.
- It overlaps with patents on caspase inhibitors, such as U.S. Patent 5,736,137 (caspase inhibitors), but claims specific cyclic peptide structures.
Competitor landscape:
- Several patent families address peptide caspase inhibitors, with filings from companies like Pfizer, Merck, and biotech firms.
- The patent's focus on cyclic peptides provides a narrower niche compared to linear peptide inhibitors or small molecules.
- Its priority date (2001) situates it early in the apoptosis inhibitor patent race, especially for peptide-based therapeutics.
Legal status:
- No record of litigation or patent challenges noted publicly.
- The patent contains no terminal disclaimers or re-examination records as of the last update.
Implications for drug development and licensing
- The broad method claims covering apoptosis inhibition via cyclic peptides are potentially enforceable against direct competitors developing similar cyclic peptide inhibitors.
- Narrow peptide sequence claims limit scope but could be used to license specific compounds.
- The patent's expiration date is October 22, 2020, subject to possible patent term adjustments or extensions.
Usage considerations:
- Since the patent has expired, licensing restrictions on this specific technology are lifted.
- Any subsequent development would need to avoid infringement of narrower, active claims or rely on design-around strategies.
Key Takeaways
- U.S. Patent 6,468,967 covers cyclic peptide-based methods and compositions inhibiting apoptosis, with particular focus on caspase activity.
- The patent's claims include specific peptide structures, pharmaceutical compositions, and treatment methods for diseases like neurodegeneration.
- It exists within a dense patent landscape of apoptosis inhibitors, with prior art emphasizing linear peptides and small molecules.
- Expired as of 2020, it has limited future enforcement potential but remains relevant historically for cyclic peptide apoptosis inhibitors.
FAQs
1. What are the main therapeutic targets for the compounds claimed in Patent 6,468,967?
The patent targets diseases involving excessive apoptosis, including neurodegenerative diseases, ischemic conditions like stroke, and HIV-related illnesses.
2. How broad are the patent claims?
The method claims are broad, covering any cyclic peptide or mimetic capable of inhibiting caspase activity, but specific peptide sequences are more limited.
3. Does the patent cover all types of apoptosis inhibitors?
No. It specifically covers cyclic peptides and peptidomimetics designed to inhibit caspases, not small molecules or linear peptides.
4. How does this patent compare to other apoptosis-related patents?
It focuses on cyclic peptides, providing a narrower scope than patents covering linear peptides or small molecule inhibitors.
5. Is the patent still enforceable?
No. It expired on October 22, 2020, after which it no longer provides patent rights.
References
[1] U.S. Patent No. 6,468,967. (2002). "Methods for inhibiting apoptosis and treating diseases associated with apoptosis." Willing, J., et al.
[2] NIH RePORTER. (n.d.). Related apoptosis inhibitor research and patents.
[3] PatentScope. (2023). Patent family and legal status information.
[4] European Patent Office. (2021). Patent expiry dates and legal status reports.
[5] World Intellectual Property Organization. (2020). Patent landscape reports on apoptosis inhibitors.
